Delcath Systems, Inc. is a commercial-stage interventional oncology company focused on developing targeted, minimally invasive treatment options for people with primary or metastatic cancers in the liver. The company aims to address the limited options available to patients with liver metastases through hepatic delivery of cancer treatment. Its approach includes percutaneous hepatic perfusion, a procedure designed to deliver melphalan to the liver.

In the United States, Delcath offers HEPZATO KIT™ (melphalan) for Injection/Hepatic Delivery System (HDS), an FDA-approved treatment for adults with metastatic uveal melanoma. In Europe, its commercial medical device product is CHEMOSAT® Hepatic Delivery System for Melphalan, used for percutaneous hepatic perfusion (PHP). Delcath also supports research and clinical trials and provides research and educational support. Its website offers clinical and scientific publications, information about its therapy and products, and resources for patients and professionals seeking to learn more. Through its focus on liver-directed treatment, Delcath works to expand therapeutic possibilities for patients with cancers affecting the liver.